K
Kim Wals
Researcher at University of Cambridge
Publications - 13
Citations - 973
Kim Wals is an academic researcher from University of Cambridge. The author has contributed to research in topics: T cell & Viral Accessory Proteins. The author has an hindex of 10, co-authored 12 publications receiving 748 citations. Previous affiliations of Kim Wals include Netherlands Cancer Institute & University of Oxford.
Papers
More filters
Journal ArticleDOI
Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells
Iva A. Tchasovnikarova,Richard T. Timms,Nicholas J Matheson,Kim Wals,Robin Antrobus,Berthold Göttgens,Gordon Dougan,Mark A. Dawson,Paul J. Lehner +8 more
TL;DR: A nonlethal forward genetic screen in near-haploid KBM7 cells identified the HUSH (human silencing hub) complex, comprising three poorly characterized proteins, TASOR, MPP8, and periphilin; this complex is absent from Drosophila but is conserved from fish to humans.
Journal ArticleDOI
Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef
Nicholas J Matheson,Jonathan Sumner,Kim Wals,Radu Rapiteanu,Michael P. Weekes,Raphael Vigan,Julia Weinelt,Michael Schindler,Robin Antrobus,Ana S. H. Costa,Christian Frezza,Clary B. Clish,Stuart J. D. Neil,Paul J. Lehner +13 more
TL;DR: This work took a distinct, systems-level, quantitative proteomic approach to gain a comprehensive, unbiased overview of how HIV infection remodels the T cell surface, and defined a unique paradigm of HIV interference with immunometabolism.
Journal ArticleDOI
Unnatural amino acid incorporation in E. coli: current and future applications in the design of therapeutic proteins.
TL;DR: The generation of proteins that hold promise for future therapeutic applications that would be impossible to obtain without unnatural amino acid incorporation are focused on, including the generation of bi-specific antibodies and antibody drug conjugates.
Journal ArticleDOI
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.
Angelica Ortiz,Jun Gui,Farima Zahedi,Pengfei Yu,Christina Cho,Sabyasachi Bhattacharya,Christopher J. Carbone,Qiujing Yu,Kanstantsin V. Katlinski,Yuliya V. Katlinskaya,Simran Handa,Victor Haas,Susan W. Volk,Angela K Brice,Kim Wals,Nicholas J Matheson,Robin Antrobus,Sonja Ludwig,Sonja Ludwig,Theresa L. Whiteside,Cindy Sander,Ahmad A. Tarhini,John M. Kirkwood,Paul J. Lehner,Wei Guo,Hallgeir Rui,Andy J. Minn,Constantinos Koumenis,J. Alan Diehl,Serge Y. Fuchs +29 more
TL;DR: The finding that melanoma TEV downregulated type I interferon receptor and expression of IFN-inducible cholesterol 25-hydroxylase (CH25H) suggests the importance of CH25H in defense against education of normal cells by TEV and argues for the use of reserpine in adjuvant melanoma therapy.
Journal ArticleDOI
Optimal Synthetic Glycosylation of a Therapeutic Antibody
Thomas B. Parsons,Weston B. Struwe,Joseph Gault,Keisuke Yamamoto,Thomas Taylor,Ritu Raj,Kim Wals,Shabaz Mohammed,Carol V. Robinson,Justin L. P. Benesch,Benjamin G. Davis +10 more
TL;DR: The optimization of an endoglycosidase‐catalyzed glycosylation of the best‐selling biotherapeutic Herceptin, an anti‐HER2 antibody is described, allowing access to the purest natural form of herceptin to date.